Nuclear <scp>PRMT5</scp> is a biomarker of sensitivity to tamoxifen in <scp>ERα</scp> <sup>+</sup> breast cancer
2023 · EMBO Molecular Medicine · 18 citations
https://doi.org/10.15252/emmm.202217248
Y
Youenn Drouet
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
64
Papers
150
Citations
7
h-index
7
i10-index
Youenn Drouet is an academic researcher from Centre Léon Bérard. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers & Cancer Cells and Metastasis. The author has an h-index of 7, co-authored 55 publications.
ORCID: 0000-0003-2963-558XPapers by this author
worksIntegrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer
2018 · Scientific Reports · 16 citations
https://doi.org/10.1038/s41598-018-25631-1
Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort
2023 · JNCI Journal of the National Cancer Institute · 13 citations
https://doi.org/10.1093/jnci/djad092
Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
2024 · Clinical Cancer Research · 7 citations
https://doi.org/10.1158/1078-0432.ccr-24-0195
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation
2024 · European Journal of Cancer · 5 citations
https://doi.org/10.1016/j.ejca.2024.115072
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat